Bristol Myers Squibb

The pharmaceutical company behind Cobenfy (xanomeline and trospium chloride), the first antipsychotic with a non-dopamine mechanism approved in over 50 years. - Commercializing Cobenfy for schizophrenia

Every atypical antipsychotic approved since the early 1990s has worked the same basic way: blocking dopamine receptors in the brain. In the past 17 months, the Food and Drug Administration (FDA) has approved three new psychiatric drugs—including Cobenfy, the first schizophrenia treatment with a genuinely novel mechanism in over 50 years, and now Bysanti, a new chemical entity from Vanda Pharmaceuticals cleared for both bipolar I disorder and schizophrenia. For the roughly 7 million Americans living with these conditions, the options just got meaningfully wider.

Updated 7 days ago

Maker of Sotyktu, the first approved oral TYK2 inhibitor and Takeda’s most direct comparator. - Incumbent oral TYK2 competitor via Sotyktu; a key benchmark for Takeda

Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don’t. Takeda’s once-daily TYK2 pill zasocitinib just cleared pivotal Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).

Updated Dec 18, 2025